Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).

Tell Us About Your Project! Get a Quote »